Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends
XTalks
AUGUST 2, 2023
This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Other drugs also contributed to Merck’s revenue growth. Toujeo generated Sanofi €1.12 Lagevrio made up a large proportion of Merck’s revenue increase with $5.68
98 
Let's personalize your content